Burgmaier Kathrin, Brandt Joy, Shroff Rukshana, Witters Peter, Weber Lutz T, Dötsch Jörg, Schaefer Franz, Mekahli Djalila, Liebau Max C
Department of Pediatrics, University Hospital of Cologne, Cologne, Germany.
Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
Front Pediatr. 2018 Jun 4;6:164. doi: 10.3389/fped.2018.00164. eCollection 2018.
Autosomal recessive polycystic kidney disease (ARPKD) is a severe hepatorenal disorder of childhood. Early renal disease in ARPKD may require renal replacement therapy and is associated with failure to thrive resulting in a need for nasogastric tube feeding or gastrostomy. In ARPKD patients, the benefit of a gastrostomy in nutrition and growth needs to be weighed against the potential risk of complications of congenital hepatic fibrosis (CHF) and portal hypertension like variceal bleeding. CHF in ARPKD has thus been considered as a relative contraindication for gastrostomy insertion. Yet, data on gastrostomies in pediatric patients with ARPKD is lacking. We conducted a web-based survey study among pediatric nephrologists, pediatric hepatologists and pediatric gastroenterologists on their opinions on and experiences with gastrostomy insertion in ARPKD patients. 196 participants from 39 countries shared their opinion. 45% of participants support gastrostomy insertion in all ARPKD patients, but portal hypertension is considered to be a contraindication by a subgroup of participants. Patient-specific data was provided for 38 patients indicating complications of gastrostomy that were in principal comparable to non-ARPKD patients. Bleeding episodes were reported in 3/38 patients (7.9%). Two patients developed additional severe complications. Gastrostomy was retrospectively considered as the right decision for the patient in 35/38 (92.1%) of the cases. This report on the results of an online survey gives first insights into the clinical practice of gastrostomy insertion in ARPKD patients. For the majority of participating physicians benefits of gastrostomy insertion retrospectively outweigh complications and risks. More data will be required to lay the foundation for clinical recommendations.
常染色体隐性多囊肾病(ARPKD)是一种严重的儿童肝肾疾病。ARPKD早期肾病可能需要肾脏替代治疗,且与生长发育不良有关,导致需要鼻饲或胃造口术。对于ARPKD患者,胃造口术在营养和生长方面的益处需要与先天性肝纤维化(CHF)和门静脉高压(如静脉曲张出血)并发症的潜在风险相权衡。因此,ARPKD中的CHF被视为胃造口术插入的相对禁忌证。然而,关于ARPKD儿科患者胃造口术的数据尚缺乏。我们对儿科肾病学家、儿科肝病学家和儿科胃肠病学家进行了一项基于网络的调查研究,了解他们对ARPKD患者胃造口术插入的看法和经验。来自39个国家的196名参与者分享了他们的意见。45%的参与者支持对所有ARPKD患者进行胃造口术插入,但一部分参与者认为门静脉高压是禁忌证。为38名患者提供了特定患者数据,表明胃造口术的并发症与非ARPKD患者基本相当。38名患者中有3名(7.9%)报告了出血事件。两名患者出现了其他严重并发症。在38例病例中的35例(92.1%)中,胃造口术被回顾性认为是对患者的正确决定。这份关于在线调查结果的报告首次深入了解了ARPKD患者胃造口术插入的临床实践。对于大多数参与的医生来说,胃造口术插入的益处回顾起来超过了并发症和风险。需要更多数据为临床建议奠定基础。